Redmile Group, LLC has filed its 13F form on May 15, 2024 for Q1 2024 where it was disclosed a total value porftolio of $2.54 Billion distributed in 77 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Krystal Biotech, Inc. with a value of $268M, Amicus Therapeutics, Inc. with a value of $156M, Immunome Inc. with a value of $121M, Scholar Rock Holding Corp with a value of $114M, and Fate Therapeutics Inc with a value of $96.7M.

Examining the 13F form we can see an increase of $6.46M in the current position value, from $2.53B to 2.54B.

Redmile Group, LLC is based out at San Francisco, CA

Below you can find more details about Redmile Group, LLC portfolio as well as his latest detailed transactions.

Portfolio value $2.54 Billion
Healthcare: $2.52 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History


  • Portfolio
  • No. of Stocks 77
  • Current Value $2.54 Billion
  • Prior Value $2.53 Billion
  • Filing
  • Period Q1 2024
  • Filing Date May 15, 2024
  • Form Type 13F-HR
  • Activity in Q1 2024
  • New Purchases 16 stocks
  • Additional Purchases 22 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 27 stocks
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.


Stay updated on Redmile Group, LLC with notifications on news.